NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- via CannabisNewsWire – CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for the cannabis industry, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a client of CNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.
The publication, titled “Biotech Market Banking on Big Cannabis Returns,” highlights the potential of specialty biotech companies as they pursue their share of the explosive growth expected in the cannabis-derived pharmaceutical market.
To view the full publication, visit: https://www.cannabisnewswire.com/biotech-market-banking-big-cannabis-returns/
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) market traction is based on the company’s proprietary cannabinoid biosynthesis technology, one of three of its core assets and one which serves as the base for its development of its drug-development pipeline of novel therapeutics that leverage the pharmacological benefits of cannabinoids like CBD. … The company is currently developing two products in its drug pipeline headed for clinical trials; INM-750, for the treatment of Epidermolysis Bullosa, and INM-085, for the treatment of Glaucoma. Additionally, the company continues to advance its INM-405 candidate for the treatment of chronic and severe pain.
InMed’s INM-750 for Epidermolysis Bullosa, an orphan disease characterized by extremely fragile skin, has potential global market revenues estimated at $1 billion per year. Another candidate in the pipeline, INM-085 for Glaucoma, has a global market potential in excess of $5 billion, and the company’s development of INM-405 targets the $36+ billion pain market.
In October, InMed provided an update on its pain program with additional pre-clinical results suggesting that peripheral application of certain CBD compounds, either alone or in combination, is effective in the treatment of craniofacial muscle pain disorders without any observed side effects to the central nervous system (http://nnw.fm/1Os9A). With increased pressure for the pharma industry to find non-addictive pain management alternatives with limited side effects, InMed continues to research the potential of non-THC cannabinoids to treat pain using a topical formulation.
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company. For more information, visit www.InMedPharma.com.
About CannabisNewsWire (CNW)
CannabisNewsWire (“CNW”) is a specialized information service that (1) aggregates cannabis news, (2) provides CannabisNewsBreaks that quickly updates investors in the space, (3) enhances corporate press releases, (4) helps companies with distribution and optimization of social media, and (5) delivers comprehensive corporate communication solutions. CNW is uniquely positioned in the cannabis market with a strong team of journalists and writers who can help private and public companies reach a wide audience of investors, consumers, journalists and the general public through our ever-growing dissemination network of more than 5,000 key syndication outlets. CNW is bringing unparalleled visibility, recognition and content to the cannabis industry.
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://CNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
CNW Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net